Fresenius Medical Care AG

Fresenius Medical Care AG

38.80
EUR
+0.33
(+0.86%)
4.23EPS
11.75P/E
10.46BMarket Cap
Nov 03Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
34.82
43.06
50.76
54.19
58.01
53.98
57.74
60.73
60.14
66.15
66.3
65.9
67.4
69.28
Basic EPS, GAAP
2.65
2.84
3.14
3.74
4.17
6.47
3.96
3.96
3.31
2.3
1.7
1.83
3.36
3.34
Free Cash Flow per Basic Share
3.07
2.53
2.98
3.28
4.07
3.28
4.76
10.82
5.58
4.92
6.63
5.75
6.06
6.36
Dividend per Share
0.71
0.86
0.78
0.8
0.96
1.06
1.17
1.19
1.34
1.35
1.12
1.19
1.45
- -
Book Value per Share
22.18
25.76
29.62
32.58
32.04
38.32
40.08
38.29
43.34
47.68
46.42
49.68
47.66
47.19
Tangible Book Value per Share
-7.64
-12.3
-11.91
-12.35
-9.68
-3.69
-11.68
-10.67
-10.66
-11.32
-8.15
-6.69
-5.43
-10.11
Basic Weighted Avg Shares
304
302
304
306
307
307
303
294
293
293
293
293
291
280
Sales/Revenue/Turnover
10,580
13,019
15,455
16,570
17,784
16,547
17,477
17,859
17,619
19,398
19,454
19,336
19,628
19,427
Operating Margin (%)
15.26
14.08
13.59
14.1
12.76
13.03
12.56
12.37
10.55
7.5
7.59
7.59
9.31
10.11
Depreciation Expense
469
575
648
702
735
790
1,593
1,786
1,624
1,838
1,752
1,742
1,500
1,557
Net Income, GAAP
804
860
955
1,144
1,280
1,982
1,200
1,164
969
673
499
538
978
938
Effective Tax Rate (%)
32.04
31.66
31.82
30.58
22.18
18.67
21.83
25.85
22.45
26.65
29.1
29.9
21.22
20.93
Profit Margin (%)
7.6
6.6
6.18
6.9
7.2
11.98
6.86
6.52
5.5
3.47
2.57
2.78
4.98
4.83
Working Capital
1,979
2,665
2,395
1,585
1,074
1,579
106
1,219
710
1,736
2,590
2,263
1,653
512
LT Debt
5,610
7,413
7,183
6,833
5,795
5,046
10,525
10,683
10,735
11,176
10,489
9,761
8,598
8,638
Total Equity
6,869
8,247
9,600
11,051
10,828
12,902
13,227
12,331
13,979
15,449
14,827
15,769
14,283
13,531
Return on Invested Capital (%)
8.34
8.63
8.57
9.02
9.75
12.72
7.43
6.55
5.47
3.93
3.46
3.6
5.49
5.74
Return on Capital (%)
7.01
6.63
6.03
6.35
7.1
10.86
5.67
4.63
3.82
2.56
2.04
2.31
4.12
3.98
Return on Common Equity (%)
11.96
11.89
11.36
12.03
12.93
18.37
10.12
10.05
8.11
5.05
3.61
3.82
7.02
7.26

Capital Structure

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2,197
2,389
2,325
LT Borrowings
5,692
5,741
5,825
LT Finance Leases
2,906
2,899
2,814
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
279
270
266
Market Capitalization
11,289
10,469
10,461

Working Capital

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
7,898
8,108
7,689
Cash, Cash Equivalents & STI
1,821
1,623
1,449
Accounts Receivable, Net
3,161
3,582
3,350
Inventories
2,141
2,303
2,332
Total Current Liabilities
6,245
6,730
7,178
Payables & Accruals
1,378
1,042
1,125
ST Debt
2,197
2,389
2,325
Deferred Revenue
114
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.48%
3.36%
-9.42%
Free Cash Flow
14.54%
-6.84%
4.67%
Net Income, GAAP
6.06%
3.3%
81.88%
Sales/Revenue/Turnover
2.53%
1.99%
1.51%
Total Cash Common Dividend
6.51%
4.58%
21.01%

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4,725
4,766
4,760
5,085
19,336
2025
4,881
4,792
4,885
5,070
19,628
2026
4,612
4,861
- -
- -
- -

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.24
0.64
0.73
0.23
1.83
2025
0.52
0.77
0.94
1.14
3.36
2026
0.43
0.81
- -
- -
- -

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.19
2025
- -
- -
- -
- -
1.45
2026
- -
- -
- -
- -
- -

Company Description

CEO
Shervin Joe Korangy
Full Time Employees
111,024
Sector
Health services
Industry
Medical/Nursing services
Address
Else-KrOener Strasse 1 Bad Homburg HE Germany 61352
IPO Date
Oct 2, 1996
Business
Fresenius Medical Care AG & Co. KGaA Fresenius Medical Care AG & Co. KGaA operates as the world's leading provider of products and services for individuals with chronic kidney diseases, including end-stage renal disease, through a global network of approximately 3,700 dialysis clinics serving more than 299,000 patients and around 40 production sites worldwide. The company offers a comprehensive portfolio of dialysis products and services, including dialysis machines such as the 2008T BlueStar system, dialyzers like Optiflux, reverse osmosis water treatment systems, related disposables, renal pharmaceuticals for treating anemia and mineral bone disorders, peritoneal dialysis solutions including Liberty Select and CLiC systems, acute kidney injury therapies such as continuous renal replacement therapy, home hemodialysis and peritoneal dialysis programs, vascular access management, and clinical laboratory and diagnostic testing services. Headquartered in Bad Homburg v. d. Höhe, Germany, with North American headquarters in Waltham, Massachusetts, Asia-Pacific headquarters in Hong Kong, and Latin America headquarters in Rio de Janeiro, Fresenius Medical Care was founded in 1996 through the merger of Fresenius AG's dialysis division and U.S.-based National Medical Care, and maintains significant operations across North America, Europe, Asia-Pacific, and Latin America targeting dialysis clinics, hospitals, intensive care units, and patients requiring renal care. Recent developments include the ongoing FME Reignite strategy and FME25+ transformation program, which delivered EUR 47 million in additional benefits during the third quarter of 2025; an increased ownership stake in value-based care provider Interwell Health through a EUR 312 million investment; integration of Fresenius Health Partners, InterWell Health, and Cricket Health to manage care for 270,000 kidney disease patients; the prior acquisition of NxStage Medical, anticipated to enhance earnings; and portfolio optimization transactions in 2024 and 2025 as part of strategic realignments.

Company News

  • Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO™

  • Fly Alliance to Replace Entire Flight Management System with flyExclusive's AI-Powered Contrails FMS

  • Fresenius Medical Care presents new evidence and innovations advancing kidney care at ASN Kidney Week 2026

  • Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now

  • Fresenius Medical Care Reshapes China Portfolio for Long-Term Growth

  • Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock Has Consensus Price Target of $23.57 According to Brokerages

  • Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market Leadership

  • Tidal Investments LLC Buys 48,885 Shares of Fresenius Medical Care AG & Co. KGaA $FMS

  • Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?

  • Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now

  • Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Share Price Passes Above 200 Day Moving Average – Time to Sell?

  • 3 Cheap International Stocks to Buy

  • Fresenius Medical Care AG & Co. KGaA Q2 Earnings Call Highlights

  • FMS Q2 Earnings Rise on Care Delivery, Revenues Miss, Margins Expand

  • Silicon Motion Showcases Next-Generation Storage Solutions for Agentic AI Applications at FMS 2026

  • Silicon Motion Showcases Next-Generation Storage Solutions for Agentic AI Applications at FMS 2026

  • Fresenius Medical Care AG (FMS) Q2 2026 Earnings Call Transcript

  • Fresenius Medical Care AG & Co. KGaA Q2 Earnings Call Highlights

  • Fresenius Medical Care Shares Drop After U.S. Treatment Volumes Fall Further

  • Kioxia Showcases Flash Storage Innovations for the AI Era at FMS 2026